Recordati Industria Chimica E Farmaceutica SpA

Recordati faces a €10.9 bn takeover bid from CVC Capital, sparking a market sell‑off and raising questions on valuation, debt, and future R&D synergies.

Recordati Industria Chimica e Farmaceutica SpA has maintained a steady performance in the pharmaceutical industry, with stable financials and a moderate valuation.

Recordati Industria Chimica e Farmaceutica SpA has announced a three-year plan to drive growth and innovation, setting ambitious financial targets and positioning itself for success despite market volatility.